Abstract
Stroke is the third most common cause of death, particularly of the elderly. Despite considerable advances in knowledge about the mechanisms of cell death after stroke, a treatment for stroke remains exclusive. For a long time, estrogen was thought of only as a “sex hormone”. Studies have documented that estrogen plays an important role in regulating behavioral and physiological events beyond the reproductive system. Most animal studies have shown that estrogens exert neuroprotective and neurogenesis effects in vivo and in vitro after ischemic stroke. However, clinical and epidemiological evidence shows that estrogen increases the risk of coronary heart disease, stroke, and breast cancer. The discrepancy between animal studies and clinical data emphasizes the importance of performing further investigations using appropriate animal models, and gaining a deeper understanding of the mechanisms of estrogen-mediated neuroprotection and neurogenesis. This review focuses on recent advances in estrogen-mediated neuroprotection and neurogenesis after ischemic stroke, highlighting its potential molecular and cellular mechanisms
Keywords: Estrogen, ischemia, stroke, neuroprotection, neurogenesis, receptor, Ers, inflammation, oxidative stress, excitotoxicity
Current Drug Targets
Title: Estrogen, Neuroprotection and Neurogenesis after Ischemic Stroke
Volume: 13 Issue: 2
Author(s): Bei Shao, Yifan Cheng and Kunlin Jin
Affiliation:
Keywords: Estrogen, ischemia, stroke, neuroprotection, neurogenesis, receptor, Ers, inflammation, oxidative stress, excitotoxicity
Abstract: Stroke is the third most common cause of death, particularly of the elderly. Despite considerable advances in knowledge about the mechanisms of cell death after stroke, a treatment for stroke remains exclusive. For a long time, estrogen was thought of only as a “sex hormone”. Studies have documented that estrogen plays an important role in regulating behavioral and physiological events beyond the reproductive system. Most animal studies have shown that estrogens exert neuroprotective and neurogenesis effects in vivo and in vitro after ischemic stroke. However, clinical and epidemiological evidence shows that estrogen increases the risk of coronary heart disease, stroke, and breast cancer. The discrepancy between animal studies and clinical data emphasizes the importance of performing further investigations using appropriate animal models, and gaining a deeper understanding of the mechanisms of estrogen-mediated neuroprotection and neurogenesis. This review focuses on recent advances in estrogen-mediated neuroprotection and neurogenesis after ischemic stroke, highlighting its potential molecular and cellular mechanisms
Export Options
About this article
Cite this article as:
Shao Bei, Cheng Yifan and Jin Kunlin, Estrogen, Neuroprotection and Neurogenesis after Ischemic Stroke, Current Drug Targets 2012; 13 (2) . https://dx.doi.org/10.2174/138945012799201702
DOI https://dx.doi.org/10.2174/138945012799201702 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Serpin Regulation of Fibrinolytic System: Implications for Therapeutic Applications in Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry ErbB4 and its Isoforms: Patentable Drug Targets?
Recent Patents on DNA & Gene Sequences Blood Atherogenicity as a Target for Anti-atherosclerotic Therapy
Current Pharmaceutical Design Progress in Therapies for Myocardial Ischemia Reperfusion Injury
Current Drug Targets Subject Index to Volume 3
Current Gene Therapy Endothelial Activation. Sliding Door to Atherosclerosis
Current Pharmaceutical Design Animal Models of Atherosclerosis Progression: Current Concepts
Current Drug Targets - Cardiovascular & Hematological Disorders The Role of Fatty Acids in the Activity of the Uncoupling Proteins
Current Chemical Biology Cardiac Regeneration by Progenitor Cells: What Is It Known as and What Is It Still to Be Known as?
Cardiovascular & Hematological Agents in Medicinal Chemistry Dendritic Cells: A Double-Edge Sword in Atherosclerotic Inflammation
Current Pharmaceutical Design Nitric Oxide Production and Signaling in Inflammation
Current Drug Targets - Inflammation & Allergy Cellular and Biochemical Actions of Melatonin which Protect Against Free Radicals: Role in Neurodegenerative Disorders
Current Neuropharmacology Alpha-1 Antitrypsin Deficiency: Current Perspective from Genetics to Diagnosis and Therapeutic Approaches
Current Medicinal Chemistry Zinc and Cell Signaling During Inflammation: Implications in Atherosclerosis
Current Nutrition & Food Science Systemic Hypertension in Patients with Aortic Stenosis: Clinical Implications and Principles of Pharmacological Therapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Evaluation of the Anti-Hypercholesterolemic and Antioxidant Activity of Mentha pulegium (L.) Aqueous Extract in Normal and Streptozotocin- Induced Diabetic Rats
The Natural Products Journal The Effects of Lipid-Regulating Therapy on Haemostatic Parameters
Current Pharmaceutical Design Chemoprevention of Colorectal Cancer: Ready for Routine Use?
Current Topics in Medicinal Chemistry The Role of Inflammatory Biomarkers in the Detection and Therapy of Atherosclerotic Disease
Current Vascular Pharmacology Asymptomatic Primary Hyperparathyroidism: Management and Implications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery